Detail akcie Immutep Rg online

Business Summary: Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
Financial Summary: BRIEF: For the six months ended 31 December 2018, Immutep Ltd revenues decreased 42% to A$2.5M. Net loss increased from A$4.3M to A$8.7M. Revenues reflect Cancer Immunotherapy segment decrease of 46% to A$2.3M, Unallocated segment decrease of 6% to A$1.3M. Higher net loss reflects Research and development and intellectua increase of 63% to A$7.6M (expense), Net gain on fair value movement of warra decrease of 45% to A$733K (income).